It is well established that overuse of short-acting beta-agonists (SABA) increases the risk of poor asthma control, exacerbations, and increased mortality.  Several studies have combined a beta-agonist with an inhaled corticosteroid (ICS). The combination provides symptom relief and decreases the risk of poor outcomes.  The days of using albuterol monotherapy should be coming to an end; two drugs are better than one!

Guest Authors:  Katherine Montag Schafer, PharmD, BCACP, CDCES and Stefanie C. Nigro, PharmD, BCACP, CDCES

Music by Good Talk